14) Newer emerging #biomarkers with current 2L approvals are: ➡️ EGFR ex20 ins: Capmatinib, Tepotinib: https://t.co/Mik8jrk7k5 ➡️ ERBB2 mutations: TDx-d https://t.co/Qn3Z4av7gP https://t.co/0K9vjCRslI
468 followers
533 followers
14) Newer emerging #biomarkers with current 2L approvals are: ➡️ EGFR ex20 ins: Capmatinib, Tepotinib: 🔓https://t.co/jzV8mZeNuK ➡️ ERBB2 mutations: TDx-d 🔓https://t.co/m4bP3IGFLX https://t.co/qwRInfqCAy
2,183 followers
📣 In this review: Researchers present recent clinical research and treatments used for epidermal growth factor receptor ex20ins mutations, summarize the latest data on emerging therapies, and discuss future prospects and treatments. #LungCancer 📚 https:/
906 followers
New article: EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives https://t.co/gaS9ZqpgxF #lungcancer #oncology https://t.co/iN1okECfPl